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Background: Actinic Cheilitis (AC) is a pathological condition of the labial mucosa considered potentially malig-
nant. The aim of this study was to investigate the effect of treatment of AC with daily use of a vitamin-based barrier 
cream.
Material and Methods: For this clinical study, 36 participants with lower-lip AC were recruited from three oral 
medicine services. At baseline, participants were evaluated by clinical examination and clinical severity of AC was 
classified as grade I to IV. All participants were dispensed a tube of a barrier cream containing vitamins A, D, E 
and ZnO to apply once nightly for 90 consecutive days. Monthly follow-up was performed to reclassify AC clinial 
severity. The primary outcome of interest was clinical remission of AC at 90-day follow-up compared to baseline. 
Results: Progressive remission of AC lesions was observed as early as the first month and throughout the assess-
ment period (p = 0.000). The 3-month period was insufficient for  remission of lesions, especially among male 
participants (p = 0.002) and with a longer sun exposure in years (p = 0.007).
Conclusions: Daily use of the vitamin-based barrier cream had a promissing positive impact on the severity of ac-
tinic cheilitis. However, a 90-day course of treatment was not sufficient to achieve lesions remission. The findings 
of this study suggest a promising new avenue for the treatment of lower-lip AC.
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Introduction
Actinic cheilitis (AC) is a pathological condition of the 
labial mucosa, often affecting the lower lip, which is 
characterized by a chronic inflammatory process caused 
by labial senility resulting from excessive, continuous 
ultraviolet radiation (UVR) exposure (1). AC is conside-
red potentially malignant due to the risk of transforma-
tion into squamous cell carcinoma (SCC) of the lip (2,3). 
However, there are no follow-up studies of untreated AC 
that would allow estimation of annual malignant trans-
formation rates (4). The overall prevalence of QA has 
been reported to range between 0.45% and 2.4% (2). It is 
most frequent in fair-skinned males, between the fourth 
and fifth decades of life, with a history of occupational 
sun exposure (2,5,6); the prevalence rises to approxima-
tely 44% in this population (2,6). 
The clinical appearance of AC lesions varies widely, 
from slight dryness or chapped lips to frank leukopla-
kia and/or ulcerations. The aspect of these lesions is not 
always consistent with the histopathological spectrum 
of epithelial alterations, which include atrophy, hyper-
keratosis, and even dysplasia of varying degrees, which 
portends transformation to SCC (2,3). Another factor to 
be considered is the delay in diagnosis due to the charac-
teristic asymptomatic nature of AC, which has impacts 
on both indications for and efficacy of treatment. In ad-
dition, AC patients rarely used lip photoprotection as a 
prevention method (7).
Among several available treatment modalities, the most 
commonly used options are vermilionectomy (“lip sha-
ve”), CO2 laser ablation, photodynamic therapy, and che-
motherapeutic agents (8-11). However, patient reports of 
discomfort and cosmetic and functional sequelae, espe-
cially after surgical treatment, have recently prompted the 
use of minimally invasive therapies. Topical medications 
are being investigated; these interventions are associated 
with a lower rate of adverse events (11).
Vitamin-based therapies have been used to reverse cu-
taneous photodamage and in the treatment of field can-
cerization (12,13), with particularly promising results 
for vitamin A analogs. Applied topically, retinoic acid 
and other metabolites of vitamin A have been used to 
fight the signs of photoaging and are capable of rever-
sing the photodamage caused by excessive sun exposu-
re, especially in actinic keratoses; furthermore, they are 
safe for long-term use (12,14). Topical use of vitamin D 
(cholecalciferol) and related active ingredients has been 
shown to reduce cell death and curtail excess proteolytic 
activity in the epidermis, with consequent improvement 
in skin hydration and, when combined with other agents, 
reductions in the number of actinic keratoses and their 
adverse effects (15-18).  Vitamin E (tocopherol), an an-
tioxidant capable of mitigating tissue damage caused by 
free radicals, appears promising to reduce photoinduced 
skin damage when used topically (19). 
The used of barrier cream containing vitamins and mine-
rals, indicated for the treatment of dermatitis, contains as 
its active ingredient vitamin D and zinc oxide (ZnO) (19, 
20). However, there have been no reports on the use of 
these vitamins on the lip epithelium or in the treatment 
of AC. Thus, the present study was designed to investi-
gate the clinical effect of treatment of actinic cheilitis 
(AC) lesions with daily use of a barrier cream containing 
vitamins A, D, E and ZnO.
Material and Methods
-Study design and ethical considerations
This clinical preliminary single-arm study was approved 
by the Research Ethics Committee of the Lutheran Uni-
versity of Brazil (protocol nº 2,751,893) and conducted 
in accordance with National Health Council Resolution 
466/12.
-Study sample and setting
The sample consisted of individuals recruited from three 
oral medicine services located in different municipali-
ties of south of Brazil.
Sample size calculation, with a statistical power of 80% 
and a significance level of 5%, was estimated by a mean 
(SD) difference of 0.63 (0.9) grades of AC severity from 
baseline after treatment, based on a pilot study by the au-
thors. The minimum sample size was established as 30 
participants. To account for possible losses to follow-up, 
an additional six participants were included (n = 36).
Participants entered the study consecutively, and un-
derwent monthly follow-up until each had individually 
completed a 90-day treatment period.
-Eligibility criteria
Adult participants (age ≥18 years) of both sexes with a 
clinical diagnosis of lower-lip AC were deemed eligible. 
Participants with presence of leukoplakia and/or labial 
ulcerations, a history or treatment of head and neck can-
cer, previous history of skin-cancer, diabetes mellitus, 
immunosuppression, or known allergy to any of the 
components of the study drug were excluded.
-Intervention and control groups
After an interview to collect sociodemographic (gen-
der, age, education level, household income), behavio-
ral (sun exposure, smoking, alcohol intake), and clini-
cal (medical and dental history) variables, participants 
underwent clinical examination and photographs were 
obtained with a 720p HDR digital camera (Apple Inc.) 
at 240fps for evaluation. Using a scheme adapted from 
Poitevin et al. (21), AC severity was classified as grade 
I (dryness and/or peeling of the surface of the vermilion 
of the lips); grade II (atrophy of the vermilion border 
of the lip with a slightly pale, raised surface and loss of 
sharpness of the boundary between skin and vermilion 
border, or presence of a melanotic line); grade III (any 
of the above, plus presence of rough and scaly areas of 
hyperkeratosis invading the inner mucosa of the lip); or 
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grade IV (any of the above plus erosion). All procedures 
were performed by two previously trained examiners. 
The classification of lesions before the treatment inter-
vention was intended to serve as an individual baseline 
control for each participant.
For treatment of AC lesions, each participant received a 
45g tube of a barrier cream containing vitamins A, D, E 
and ZnO (Hipoglós®, Johnson & Johnson) and were gi-
ven verbal and written instructions to apply a thin layer 
to the upper and lower lips once nightly for 90 consecu-
tive evenings. All were instructed not to eat or drink for 
at least 1 hour after application. Furthermore, each parti-
cipant received a stick of Protective Lip Balm (SPF 30) 
and was instructed to apply it during the day or before 
any sun exposure. 
Throughout the observation period, participants were 
asked to bring the ointment tube to each study visit for 
confirmation of treatment adherence. Once treatment 
had begun, participants returned for follow-up visits at 
30, 60, and 90 days. At each visit, two examiners perfor-
med all procedures as at baseline. A third examiner an 
expert in oral medicine, and blinded to clinical informa-
tion, reviewed all photographs to confirm the classifica-
tion of AC severity grade in each participant at each time 
point of assessment.
Photographs were obtained at a standard distance, and 
resolution and viewed in a dark room on a laptop com-
puter (Apple Inc.). Images from each time point were 
selected randomly by the third examiner for evaluation 
every 14 days. Kappa coefficients were calculated to 
assess intra-examiner agreement. A kappa ≥0.81 (exce-
llent) was considered indicative of a valid result to allow 
reproducibility of the AC lesion classification method 
used in the study.
Throughout the observation period, participants whose 
lesions progressed in severity were immediately exclu-
ded from the sample and referred for biopsy.
For analysis of the primary outcome (lesion remission) 
and estimation of treatment effect, the baseline grade 
of severity was compared with that observed at the end 
of follow-up (90 days). The outcome was classified as: 
complete remission; partial remission; or lesion unchan-
ged (no grade change). 
-Data analysis
Data were analyzed by descriptive statistics and genera-
lized estimation equations (GEE) for longitudinal data 
analysis (observation period), adjusted by Bonferroni 
multiple comparisons. Analysis of correlation between 
variables was carried out by Student’s t-test for up to 
two groups and Spearman’s test, one-way ANOVA, and 
post-hoc tests for more than two groups. All analyses 
were performed in IBM SPSS Version 25.0 software. 
The significance level was set at p < 0.05.
Results
Of the 36 participants recruited, 35 met the eligibility 
criteria and were included in the study. During the ob-
servation period, six participants were lost to follow-up: 
four dropped out, one died, and one participant was ex-
cluded at the 60-day visit due to lesion requiring biopsy. 
Thus, 29 participants completed the study (Fig. 1).
Most participants were male (54.3%), fair-skinned 
Fig. 1: Flowchart of participants selection and follow-up.
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(91.4%), and had worked or otherwise been exposed 
to work in the sun (65.7%), for at least 8 hours daily 
(69.56%), over 20 years or longer (52.2%), and had ne-
ver worn sunscreen (60%). The mean age was 56.66 (± 
13.66) years. Many participants had low educational at-
tainment (high school or less; 48.6%), a household inco-
me of 1 to 3 times the current minimum wage (37.1%), 
and most reported some type of comorbidity (e.g., 
hypertension) (67.5%). Regarding behavioral variables, 
smoking or former smoking was reported by 91.4% of 
the sample, while current or past alcohol intake was re-
ported by 20% of participants (Table 1). 
Variable Category n (%)
Sex Male 16 (45.7%)
Female 19 (54.3%)
Age (years) Mean ± standard deviation 56.6 ± 13.66
Range 31 - 77
Skin color White 32 (91.4)
Brown 3 (8.6)
Educational attainment Primary or less 14 (40)
Secondary or less 17 (48.6)
Higher 4 (11.5)
Monthly income ≤ 1× minimum wage 11 (31.4)
1 – 3× minimum wage 13 (37.1)
> 3× minimum wage 11 (31.5)
Duration of sun exposure (years) ≤ 8 3 (12.9)
10–20 8 (34.8)
> 20 12 (52.2)
Smoking Current 19 (54.3)
Never 3 (8.6)
Former 13 (37.1)
Comorbidities Yes 23 (65.7)
No 12 (34.3)
Alcohol intake Current 3 (8.6)
Never 28 (80.0)
Former 4 (11.4)
Table 1: Distribution of sociodemographic, behavioral, and clinical variables of study participants (n = 35).
Intra-examiner agreement on the clinical severity of AC 
lesions was 94%, while inter-examiner agreement was 
excellent at κ = 0.915 (95% CI 0.688-1.00).  At baseli-
ne (n=35), the mean severity of AC lesions was 3.06 (± 
0.99), with 45.7% of participants (n = 16) having grade 
IV and 34,3% (n=12) grades I or II. Over the observation 
period, mean severity was 2.4 (± 1.10) at 30 days (n = 
32), 2.2 (± 1.24) at 60 days (n = 32), and 2.0 (± 1.51) 
at 90 days (n = 29) (Table 2). A progressive reduction 
in mean AC severity was thus observed, especially be-
tween baseline and 90 days (from 3.06 to 2.03 respec-
tively). 






Baseline 35 3.06 3.0 0.99 1-4
30-day follow-up 32 2.47 2.0 1.01 0-4
60-day follow-up 32 2.25 2.0 1.24 0-4
90-day follow-up 29 2.03 3.0 1.51 0-4
Table 2: Distribution of severity of actinic cheilitis lesions at baseline and throughout the study period.
SD: standard deviation.
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Comparison of mean severity at baseline and at 30, 60, 
and 90 days showed a significant difference in terms 
of disease regression (p = 0.000), starting at 30 days of 
treatment (Table 3). The largest difference was found on 
comparison of baseline versus the 90-day end-of-study 
visit (p = 0.000).
Time point (Mean grade) Difference in means Bonferroni Sig.* 95%CI
Baseline (3.0)





p 30 days (2.34) 0.66a 0.000 0.22–1.09
60 days (2.17) 0.83a 0.000 0.31–1.34
90 days (2.0) 1.0a 0.000 0.38–1.62
Table 3: Distribution of mean values and mean differences in actinic cheilitis severity at baseline and follow-up of partici-
pants who completed the study period (n = 29).
* p ≤ 0.05; a (significant difference).
Of the participants who completed the study (n = 29), 
27.6% (n = 8) had experienced no change in AC severity 
from baseline at 90 days. Three participants (10.3%) had 
worsening AC and were referred for biopsy. More than 
half of the sample (62%) had complete (n = 9) or partial 
(n = 9) remission of AC lesions.
There was a correlation between improvement in AC 
severity and participant gender, with worse responses 
being observed in males (p = 0.002). Furthermore, the 
longer the duration of sun exposure in years, the lower 
the rate of remission (p = 0.007). Nevertheless, no co-
rrelation was found with participant age (p = 0.138) nor 
with behavioral habits, including smoking (p = 0.930).
Discussion
The results of this study showed that daily use of a barrier 
cream containing vitamins A, D, E and ZnO had a pro-
gressive effect leading to complete or partial remission 
of lower-lip AC lesions in more than half of the sample 
(62%), regardless of baseline severity. The 3-month pe-
riod of observation was not sufficient for complete remis-
sion of AC; however, it bears stressing that about 46% 
of participants had grade IV lesions at baseline. On the 
other hand, approximately 34% of participants with grade 
IV lesions at baseline experienced two to four grades of 
improvement in clinical severity at the end of the 90-day 
period. In addition, baseline participants with severity 
grades I–III accounted for the highest proportion of cases 
achieving complete remission at 90 days. 
This effect on the remission of AC lesions may be attri-
butable to the components of the barrier cream, especia-
lly retinoic acid (vitamin A), which has been shown to 
have a positive effect on photodamage in UVR-exposed 
skin (12). Tretinoin, another vitamin A derivative, has 
been shown to reverse the effects of photoaging, with a 
23–60% progressive reduction in actinic keratoses due 
to cumulative UVR exposure. This effect is attributable 
to a reduction in the stratum corneum and restoration of 
the dermis within 120 days of treatment (12,13). This 
may perhaps explain why the 90-day observation period 
used in the present study was insufficient; use of the ba-
rrier cream for a longer period might have allowed the 
full effect of the retinol component to manifest itself, 
with the possibility of complete remission of AC lesions. 
Vitamin D, another component of the formula, in ad-
dition to keeping the lips hydrated and protected, may 
have acted synergistically with vitamin A. When combi-
ned with 5-fluorouracil (5-FU) in the treatment of acti-
nic keratoses, this vitamin has been shown to reduce the 
number of lesions and minimize adverse events of 5-FU, 
such as pain, scabbing, and skin ulceration, which also 
improves treatment tolerability (17). 
In the present study, cases classified as grade IV with 
areas of erosion had a rapid response to treatment. This 
effect is probably attributable to ZnO, another compo-
nent of the formulation. Zinc compounds are known to 
increase the potential for keratinocyte migration and 
collagenolytic activity, in addition to stimulating tissue 
reepithelization and repair (20). In addition, ZnO-con-
taining creams have been shown to induce complete re-
mission of dermatitis very rapidly (after approximately 
4 days of use) (22). 
A systematic review (11) compared different treatments 
for AC lesions and concluded that the combination of 
imiquimod with photodynamic therapy (PDT) improved 
clinical appearance in 80 to 100% of cases. However, 
it is noteworthy that most of the included studies had 
no formal sample size calculation and enrolled a small 
number of participants, which may have led to random 
error and directly impacted the methodological quality 
and heterogeneity of the available literature regarding 
the effectiveness of treatments for AC. It should also be 
noted that, in this review, the use of PDT with imiqui-
mod was implicated in a wide range of adverse effects, 
including itching, pain, redness, swelling, blistering and 
crusting, and superficial erosions and ulcerations (8). In 
the present study, participants only reported superficial 
lip desquamation in the first days of treatment. 
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The results of our study cannot be compared to those of 
invasive treatments for AC. However, there are several 
less invasive, easy-to-use, low-cost alternatives that can 
both prevent and treat AC. This is especially relevant con-
sidering as verified in the present study—the potential for 
progressive remission of severe AC lesions, which pose 
the highest risk of malignant transformation to SCC (21).
In our investigation, we found significant correlations 
between lower remission rates and longer duration of 
sun exposure (in years), only among male participants. 
Possible explanations of this result include the lower ad-
herence of men to treatments that require continuous use 
(23). Also, one must consider the cumulative effects of 
UVR exposure to the lip epithelium, which may lead to 
decreased responsiveness and tissue repair (1, 6, 24). 
Possible limitations of this study include the fact that 
clinical examination may sometimes underestimate the 
severity of AC in cases with a less aggressive appea-
rance and varying degrees of undetectable dysplasia. 
However, this possible confounding factor was mini-
mized by clinical classification of lesion severity, based 
on well-established criteria (21). Other limitation, only 
patients of 43 years or older were include in the study.
At the end of the 90-day observation period, despite the 
loss of follow-up of some participants (n = 6), a number 
close to that established by the sample size calculation 
remained. Thus, our study was able to detect a 0.66-gra-
de difference in AC severity between baseline and the 
end of the study. This can be considered a strength of the 
present study, as can the prospective follow-up of the 
participants—which allowed detection of clinical chan-
ges at any time and, especially, the possibility of com-
paring cases before and after the start of the treatment. 
Nevertheless, the promising results obtained in this pre-
liminary study with use of a vitamin-based topical the-
rapy for AC, create a perspective for further research. 
Future studies should focus on longer treatment and 
follow-up periods and enroll comparator groups to as-
certain the efficacy and effectiveness of this treatment.
Conclusions
Daily topical use of vitamin-based barrier cream has 
a promising positive impact on the clinical severity of 
actinic cheilitis. However, a 90-day course of treatment 
was not sufficient to achieve complete remission. The 
findings of this study suggest a promising new avenue 
for the treatment of lower-lip AC.
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